Bladder Cancer Weekly

February 15, 2026

Videos

Peer-to-Peer Clinical Conversations

Cohort P Data from the BOND-003 Study in BCG-Unresponsive Papillary Bladder Cancer - Mark Tyson

Mark Tyson

Mark Tyson speaks with Zachary Klaassen about Cohort P results from the BOND-003 trial evaluating cretostimogene grenadenorepvec in BCG-unresponsive papillary-only non-muscle-invasive bladder cancer.

Shifting From TURBT to Chemoablation in Low-Grade Intermediate-Risk NMIBC - Max Kates

Max Kates

Zachary Klaassen hosts Max Kates to discuss the role of intravesical mitomycin chemoablation for patients with low-grade intermediate-risk non–muscle invasive bladder cancer.

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Systematic Review of the Definition of Cure and of Curative-intent Treatments in Early Bladder Cancer.

Bacillus Calmette-Guérin Plus Mitomycin versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301) - Beyond the Abstract

Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder Cancer.

Diagnosis, evaluation, and management of patients with non-muscle invasive bladder cancer.

Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer.

Molecular characterization of non-muscle invasive tumor from N-methyl-N-nitrosourea (MNU)-induced urothelial carcinoma in a rat model reveals hallmarks of both luminal and basal subtypes.

ASO Practice Guidelines Series: Surgical Management of Bladder Cancer Relapse.

Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database.

Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte-Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin-Unresponsive Papillary-Only NMIBC

The challenge of bladder preservation in muscle invasive bladder cancer: key concepts and future directions.

Impact of pelvic lymph node dissection on oncological outcomes in patients with clinically staged non-muscle-invasive bladder cancer undergoing radical cystectomy: a systematic review.

Sarcopenia and recurrence risk in high-risk non-muscle-invasive bladder cancer: a nonlinear modeling approach.

Neoadjuvant therapy and complete response of muscle-invasive bladder cancer: may the urinary bladder be preserved?.

Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer.

Understanding Bladder Cancer Screening Limits Through Comparative Modeling: The Maximum Clinical Incidence Reduction (MCLIR) Methodology.

T Cell Subsets of Urine-Derived Lymphocytes (UDLs) Serve as an Indicator of TILs and Reflect Immunological Sex Differences in Bladder Cancer - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC